151 related articles for article (PubMed ID: 35089239)
21. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
Mora J
Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
[TBL] [Abstract][Full Text] [Related]
22. Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.
Lode HN; Ehlert K; Huber S; Troschke-Meurer S; Siebert N; Zumpe M; Loibner H; Ladenstein R
Br J Cancer; 2023 Nov; 129(11):1780-1786. PubMed ID: 37813959
[TBL] [Abstract][Full Text] [Related]
23. Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma.
Wieczorek A; Zaniewska-Tekieli A; Ehlert K; Pawinska-Wasikowska K; Balwierz W; Lode H
Front Oncol; 2023; 13():1082771. PubMed ID: 36816982
[TBL] [Abstract][Full Text] [Related]
24. Rhombencephalitis and longitudinal extensive myelitis associated with dinutuximab use in high-risk neuroblastoma.
Atak F; Aydın GB; Öncel İ; Öz S; Oğuz KK
Turk J Pediatr; 2023; 65(3):523-530. PubMed ID: 37395971
[TBL] [Abstract][Full Text] [Related]
25. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
[TBL] [Abstract][Full Text] [Related]
26. Dinutuximab for the treatment of pediatric patients with neuroblastoma.
Greenwood K; Foster JH
Drugs Today (Barc); 2017 Sep; 53(9):469-476. PubMed ID: 29238760
[TBL] [Abstract][Full Text] [Related]
27. Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series.
Ding YY; Panzer J; Maris JM; Castañeda A; Gomez-Chiari M; Mora J
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748630
[TBL] [Abstract][Full Text] [Related]
28. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
[TBL] [Abstract][Full Text] [Related]
29. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy with anti-G
Kushner BH; Modak S; Kramer K; Basu EM; Iglesias-Cardenas F; Roberts SS; Cheung NV
Int J Cancer; 2023 Jan; 152(2):259-266. PubMed ID: 35913764
[TBL] [Abstract][Full Text] [Related]
31. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
[TBL] [Abstract][Full Text] [Related]
32. Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?
Raiser P; Schleiermacher G; Gambart M; Dumont B; Defachelles AS; Thebaud E; Tandonnet J; Pasqualini C; Proust S; Entz-Werle N; Aerts I; Ndounga-Diakou LA; Petit A; Puiseux C; Khanfar C; Rouger J; Mansuy L; Benadiba J; Millot F; Pluchart C; Laghouati S; Geoerger B; Vassal G; Valteau-Couanet D; Berlanga P
Eur J Cancer; 2024 May; 202():114001. PubMed ID: 38489858
[TBL] [Abstract][Full Text] [Related]
33. Dinutuximab: first global approval.
Dhillon S
Drugs; 2015 May; 75(8):923-7. PubMed ID: 25940913
[TBL] [Abstract][Full Text] [Related]
34. Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma.
Barry WE; Jackson JR; Asuelime GE; Wu HW; Sun J; Wan Z; Malvar J; Sheard MA; Wang L; Seeger RC; Kim ES
Clin Cancer Res; 2019 Jan; 25(1):325-333. PubMed ID: 30232225
[TBL] [Abstract][Full Text] [Related]
35. Dinutuximab: A Review in High-Risk Neuroblastoma.
Hoy SM
Target Oncol; 2016 Apr; 11(2):247-53. PubMed ID: 26891967
[TBL] [Abstract][Full Text] [Related]
36. Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta.
Jain R; Trehan A; Menon P; Kapoor R; Kakkar N; Radhika S; Saxena AK; Mittal BR; Varma N; Samujh R; Bansal D
Pediatr Hematol Oncol; 2021 May; 38(4):291-304. PubMed ID: 33622164
[TBL] [Abstract][Full Text] [Related]
37. Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model.
Ornell KJ; Taylor JS; Zeki J; Ikegaki N; Shimada H; Coburn JM; Chiu B
Cancer Med; 2020 Apr; 9(8):2891-2903. PubMed ID: 32096344
[TBL] [Abstract][Full Text] [Related]
38. Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group.
Hingorani P; Krailo M; Buxton A; Hutson P; Sondel PM; Diccianni M; Yu A; Morris CD; Womer RB; Crompton B; Randall RL; Teot LA; DuBois SG; Janeway KA; Gorlick RG; Isakoff MS
Eur J Cancer; 2022 Sep; 172():264-275. PubMed ID: 35809374
[TBL] [Abstract][Full Text] [Related]
39. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience.
Olgun N; Cecen E; Ince D; Kizmazoglu D; Baysal B; Onal A; Ozdogan O; Guleryuz H; Cetingoz R; Demiral A; Olguner M; Celik A; Kamer S; Ozer E; Altun Z; Aktas S
Front Oncol; 2022; 12():1041443. PubMed ID: 36620564
[TBL] [Abstract][Full Text] [Related]
40. A Case of Anti-NMDA Receptor Encephalitis During Dinutuximab Therapy for Neuroblastoma.
Lowas SR; Lettieri CK
J Pediatr Hematol Oncol; 2021 Jan; 43(1):e127-e129. PubMed ID: 31651725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
